Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Cash runway to fund pipeline development and operations into the first half of 2028

EPRX

<p>在接受 EP-104GI 單次治療後，觀察到持續的症狀和組織反應，持續時間達到 52 周。RESOLVE 試驗的第 2b 階段仍在招募中，預計將在 2026 年第三季度公佈初步數據。現金流將支持管線開發和運營，持續到 2028 年上半年</p>

Eupraxia Pharmaceuticals 公佈 2025 年第三季度財務結果